← Back to Search

Monoclonal Antibodies

Elranatamab for Multiple Myeloma

Phase 3

Recruiting

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.

Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 5 years

Awards & highlights

Study Summary

"This trial is testing a new medication called elranatamab for the treatment of a type of cancer called MM. Participants in the trial must be 18 years or older with MM that has returned

Who is the study for?

This trial is for adults with Multiple Myeloma (MM) that has returned or hasn't responded after treatment, including anti-CD38 antibody and lenalidomide. Participants must have had 1 to 4 prior MM treatments, meet specific lab value criteria, not be pregnant or breastfeeding, and agree to use contraception.Check my eligibility

What is being tested?

The study compares elranatamab—a new medication given as a weekly shot—with a combination of standard MM therapies chosen by the doctor. The goal is to evaluate elranatamab's safety and effectiveness against these common treatments.See study design

What are the potential side effects?

Potential side effects are not specified in the provided information but may include reactions at the injection site, general drug-related side effects like nausea, fatigue, blood disorders, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My last cancer treatment did not work according to IMWG standards.

Select...

My last cancer treatment did not work as expected.

Select...

I can take care of myself and am up and about more than half of my waking hours.

Select...

I have multiple myeloma and have been treated 1-4 times, including with CD38 antibody and lenalidomide.

Select...

I can take care of myself but might not be able to do heavy physical work.

Select...

I have multiple myeloma and have been treated with 1-4 therapies, including CD38 antibody and lenalidomide.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression free survival per International Myeloma Working Group criteria

Secondary outcome measures

Complete response rate per International Myeloma Working Group criteria

Duration of complete response per International Myeloma Working Group criteria

Duration of minimal residual disease negativity rate per International Myeloma Working Group criteria

+14 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: ElranatamabExperimental Treatment1 Intervention

Participants will receive elranatamab monotherapy

Group II: Investigator's ChoiceActive Control5 Interventions

Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Elranatamab

2022

N/A

~510

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor

4,570 Previous Clinical Trials

10,915,490 Total Patients Enrolled

35 Trials studying Multiple Myeloma

9,398 Patients Enrolled for Multiple Myeloma

Pfizer CT.gov Call CenterStudy DirectorPfizer

3,476 Previous Clinical Trials

8,091,708 Total Patients Enrolled

25 Trials studying Multiple Myeloma

4,708 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants still being accepted for this clinical trial?

"As per the details on clinicaltrials.gov, recruitment for this particular research endeavor has ceased. Although it was initially listed on 2/2/2024 and last updated on the same day, there are currently approximately 800 other trials actively seeking participants at this time."

Answered by AI

What is the level of safety associated with Elranatamab for individuals?

"As per our assessment at Power, the safety rating for Elranatamab is a 3 on the scale. This determination aligns with it being a Phase 3 trial that has accumulated substantial evidence backing its efficacy and safety profile."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

2024. "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06152575.

All > Denver